Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar portefeuille (99.75) Submitted: 12/15/2011 11:17:49 PM : Outperform Start Price: $6.12 HALO Score: +8.92

There are currently 1300 HALO shares in my "fund" with break-even of around 7.15 USD. http://caps.fool.com/Blogs/fund-trades/678775.

Report this Post 1 Comment
Member Avatar portefeuille (99.75) Submitted: 2/9/2012 12:08:00 AM
Recs: 0

now 1100 shares in the fund with break-even of around 6.65 USD.
http://caps.fool.com/Blogs/fund-trades/705717.
http://twitter.com/portefeuillefun.

Featured Broker Partners


Advertisement